Shares of Pfizer Inc. (NYSE:PFE) ended Thursday session in red amid volatile trading. The shares closed down -0.12 points or -0.34% at $34.72 with 18.23 million shares getting traded. Post opening the session at $34.71, the shares hit an intraday low of $34.62 and an intraday high of $34.81 and the price vacillated in this range throughout the day. The company has a market cap of $211.02 billion and the numbers of outstanding shares have been calculated to be 6.07 billion shares.
Pfizer Inc. (PFE) on September 7, 2016 announced that Dr. Ole Isacson, a world-renowned scientist and thought leader in neurology, will become Chief Scientific Officer of the Neuroscience Research Unit and Senior Vice President, effective September 16. Dr. Isacson is a Professor of Neurology at Harvard Medical School, and will continue to serve in an educational role. He is also a founding director of the Neuroregeneration Institute at McLean Hospital. Dr. Isacson will report directly to Mikael Dolsten, President of Worldwide Research and Development.
Dr. Isacson received his Medical Bachelor and Doctor of Medicine degrees from the University of Lund in Sweden and held a two year postdoctoral fellowship at Cambridge University in England before joining Harvard in 1989. Over the course of two decades, his lab has become known as one of the most recognized academic research centers for Parkinson’s disease and other neurodegenerative disorders.
“Dr. Isacson’s deep expertise in neurodegenerative disorders is well-aligned with our work in Alzheimer’s and Parkinson’s disease, where we are working to advance potential breakthrough therapies to fill the tremendous unmet need that exists for patients,” said Dr. Dolsten. “In addition, his strong ties in the local academic community will be important as our Cambridge site continues to drive collaborations with leading scientific and academic institutions that can help us speed the pace of discovery.”
Shares of Apricus Biosciences Inc (NASDAQ:APRI) ended Thursday session in green amid volatile trading. The shares closed up +0.008 points or 2.54% at $0.327 with 896,381.00 shares getting traded. Post opening the session at $0.34, the shares hit an intraday low of $0.31 and an intraday high of $0.34 and the price vacillated in this range throughout the day. The company has a market cap of $22.15 million and the numbers of outstanding shares have been calculated to be 66.35 million shares.
Apricus Biosciences Inc (APRI) on Sept. 08, 2016 announced that Argentina has granted Apricus` commercialization partner, Ferring Pharmaceuticals, market approval for Vitaros®, an on-demand topical cream indicated for the treatment of patients with erectile dysfunction.
This is the twenty-fourth country in which the product has been approved, including Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Iceland, Ireland, Italy, Lebanon, Luxembourg, the Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Spain, Sweden, Switzerland and the United Kingdom.
“We are very pleased that Vitaros has received its first approval in Latin America,” said Richard Pascoe, Chief Executive Officer of Apricus. “This approval, along with the registration filings in Mexico and Columbia, marks an important milestone for Apricus as we seek to build a global Vitaros brand. I want to congratulate our colleagues at Ferring for their efforts in building the Vitaros franchise in major markets throughout Europe and Latin America, and we look forward to Ferring obtaining additional regulatory approvals and driving revenue through additional product launches this year and next.”